Guardian Pharmacy Raises 2026 Guidance After Strong Q2, Net Income Surges on Settlement
GRDN has more than doubled off its 52-week low of $19.295.
Summary
Guardian Pharmacy reported Q2 revenue of $351.8M, up 2% YoY, with net income of $22.1M, boosted by an $8.5M payor dispute settlement. Adjusted EBITDA rose to $29.7M from $25.0M. The company raised full-year guidance: revenue to $1.43B-$1.45B and adjusted EBITDA to $129M-$131M, reflecting confidence in underlying momentum despite IRA pricing headwinds. Post-quarter, Guardian completed the Wellness Concepts acquisition and launched a greenfield pharmacy in Kentucky, expanding its footprint. Leadership changes took effect July 1 with David Morris as COO and Will Mudd as CFO. The results and guidance raise signal stronger-than-expected profitability and growth, though the settlement inflates net income. The conference call at 4:30 pm ET may provide additional color on organic trends and M&A pipeline.
At the time of this announcement, GRDN was trading at $39.47 on NYSE in the Life Sciences sector, with a market capitalization of approximately $2.5B. The 52-week trading range was $19.30 to $44.00. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: BusinessWire.